A Phase 3 interventional study of losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) and Losartan potassium in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing losartan in Essential Hypertension — none open to participants now, none under way, none of them phase 3. Losartan · Essential Hypertension.
Among the 10 studies testing losartan in Essential Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 6th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 10 studies testing losartan in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 327 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 284 across the 10 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 2 studies filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing losartan in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E). The primary hypothesis is that L50/H12.5/A5 is more effective in lowering mean trough sitting diastolic blood pressure (SiDBP) after 8 weeks of treatment compared to L50+A5 in Japanese participants with essential hypertension who are not adequately controlled following an 8-week treatment with filter period study drug (L50+A5).
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
This study's enrollment of 327 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Browse Essential Hypertension studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) · Drug: Placebo to losartan potassium · Drug: Placebo to amlodipine besylate
Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
Drug: Losartan potassium · Drug: Amlodipine besylate · Drug: Placebo to MK-0954E
Drug pages: Losartan · Hydrochlorothiazide · Amlodipine
One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
One tablet, containing placebo, orally, once daily, for 8 weeks.
One tablet, containing placebo, orally, once daily, for 8 weeks.
One capsule, containing placebo, orally, once daily, for 8 weeks.
Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.
Time frame: Baseline and Week 8
Percentage of Participants Who Experience ≥1 Adverse Event (AE)
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.
Time frame: up to 14 days after last dose of study drug (up to 10 weeks)
Percentage of Participants Who Experience ≥1 Drug-related AE
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.
Time frame: up to 14 days after last dose of study drug (up to 10 weeks)
Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE)
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.
Time frame: up to 14 days after last dose of study drug (up to 10 weeks)
Percentage of Participants Who Experience ≥1 Drug-related SAE
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received
Time frame: up to 14 days after last dose of study drug (up to 10 weeks)
Percentage of Participants Who Had Study Drug Stopped Due to an AE
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm
Time frame: up to 8 weeks
Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP)
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.
Time frame: Baseline and Week 8
| Milestone | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Started | 164 | 163 |
| Completed | 154 | 157 |
| Not completed | 10 | 6 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Blood pressure/potassium criteria met | 6 | 4 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.
| mmHg | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) | -9.1 (-10.2 to -7.9) | -8.0 (-9.1 to -6.8) |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.
| Percentage of Participants | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Percentage of Participants Who Experience ≥1 Adverse Event (AE) | 30.5 | 28.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.
| Percentage of Participants | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Percentage of Participants Who Experience ≥1 Drug-related AE | 11.6 | 3.7 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.
| Percentage of Participants | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE) | 0.6 | 0.6 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received
| Percentage of Participants | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Percentage of Participants Who Experience ≥1 Drug-related SAE | 0.0 | 0.0 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm
| Percentage of Participants | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Percentage of Participants Who Had Study Drug Stopped Due to an AE | 1.2 | 0.0 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.
| mmHg | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP) | -13.4 (-15.2 to -11.6) | -10.2 (-12.0 to -8.4) |
Collected over up to 2 weeks after last dose of study drug (up to 10 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L50/H12.5/A5 | — | 1/164 (0.6%) | 11/164 (6.7%) |
| L50 + A5 | — | 1/163 (0.6%) | 15/163 (9.2%) |
| Event | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| Sudden cardiac deathGeneral disorders | 0/164 | 1/163 |
| Clavicle fractureInjury, poisoning and procedural complications | 1/164 | 0/163 |
| Rib fractureInjury, poisoning and procedural complications | 1/164 | 0/163 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/164 | 0/163 |
| Event | L50/H12.5/A5 | L50 + A5 |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/164 | 15/163 |
| Age, Continuous(years) | L50/H12.5/A5 | L50 + A5 | Total |
|---|---|---|---|
| Mean | 54.9 ± 9.4 | 55.4 ± 10.1 | 55.2 ± 9.7 |
| Sex: Female, Male(Participants) | L50/H12.5/A5 | L50 + A5 | Total |
|---|---|---|---|
| Female | 33 | 41 | 74 |
| Male | 131 | 122 | 253 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2011 to primary completion in Apr 2012, 15 months.
Results were first posted in Jan 2017, 4 years 9 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 15 months is close to that.
Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Losartan · Hydrochlorothiazide · Amlodipine